Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

3 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

dbGaP phs000602 Identification of Targetable FGFR Gene Fusions in Diverse Cancers - Eligibility

- 11/11/22 - 4 moduli, 1 ItemGroup, 19 elementi, 1 linguaggio
ItemGroup: IG.elig
Principal Investigator: Arul M. Chinnaiyan, MD, PhD, University of Michigan, MI, USA MeSH: Neoplasms,Cholangiocarcinoma,Breast Neoplasms,Prostatic Neoplasms,Urinary Bladder Neoplasms,Mouth Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000602 In this study, patients with advanced cancer across all histologies were enrolled in our IRB approved clinical sequencing program, called MI-ONCOSEQ, to go through an integrative sequencing which includes whole exome sequencing of the tumor and matched normal, and transcriptome sequencing. Four index cases were identified which harbor gene rearrangements of FGFR2 including two cholangiocarcinoma cases, a metastatic breast cancer case, and a metastatic prostate cancer case. After extending our assessment of FGFR rearrangements across multiple tumor cohorts, including TCGA, we identified FGFR gene fusions with intact kinase domains of FGFR1, FGFR2, or FGFR3 in cholangiocarcinoma, breast cancer, prostate cancer, lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation. Overexpression of FGFR fusion proteins in vitro induced cell proliferation, and bladder cancer cell lines that harbors FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacologic inhibition in vitro and in vivo. Due to the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clinical sequencing efforts which incorporate transcriptome analysis for gene fusions are poised to identify rare, targetable FGFR fusions across diverse cancer types.

pht003221.v1.p1

1 ItemGroup 5 elementi

pht003222.v1.p1

1 ItemGroup 6 elementi

pht003220.v1.p1

1 ItemGroup 5 elementi

dbGaP phs001003 Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets - pht010322.v2.p1

- 06/11/23 - 6 moduli, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: pht010322
Principal Investigator: Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Colonic Neoplasms,Ovarian Neoplasms,Stomach Neoplasms,Cholangiocarcinoma,Pancreatic Neoplasms,Rectal Neoplasms,Esophageal Neoplasms,Colorectal Neoplasms,Endometrial Neoplasms,Paraneoplastic Syndromes, Ocular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001003 Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In this study, we performed whole exome and RNA-Seq analysis metastases to determine the nature and frequency of somatic mutations.

pht010323.v2.p1

1 ItemGroup 2 elementi

pht010324.v2.p1

1 ItemGroup 4 elementi

pht010325.v1.p1

1 ItemGroup 2 elementi

pht010326.v2.p1

1 ItemGroup 5 elementi

Eligibility

1 ItemGroup 9 elementi

Extrahepatic Bile Duct Cancer NCT01093222 Registration - Southwest Oncology Group S0941 Registration Worksheet Form - 3028434v1.0 - Southwest Oncology Group S0941 Registration Worksheet Form

- 09/01/15 - 1 modulo, 7 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Protocol Information, SWOG PATIENT ID, DEMOGRAPHY, For SWOG Institutions:, Patient Information, Indicate how the patient answered the following questions on the consent form, Patient Eligibility
Southwest Oncology Group S0941 Registration Worksheet Form Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8229FCFE-E5C8-63E1-E040-BB89AD43798D

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial